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Abstract TAK1 is a mitogen-activated protein kinase kinase
kinase (MAP3K) that is involved in the c-Jun N-terminal kinase/
p38 MAPKs and NF-UB signaling pathways. Here, we
characterized the molecular mechanisms of TAK1 activation by
its specific activator TAB1. Autophosphorylation of two
threonine residues in the activation loop of TAK1 was necessary
for TAK1 activation. Association with TAK1 and induction of
TAK1 autophosphorylation required the C-terminal 24 amino
acids of TAB1, but full TAK1 activation required additional
C-terminal Ser/Thr rich sequences. These results demonstrated
that the association between the kinase domain of TAK1 and the
C-terminal TAB1 triggered the phosphorylation-dependent
TAK1 activation mechanism.
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1. Introduction
Transforming growth factor-L (TGF-L)-activated kinase 1
(TAK1) was originally identi¢ed as a mitogen-activated pro-
tein kinase kinase kinase (MAP3K) which can be activated by
TGF-L and bone morphological protein (BMP) [1]. Associa-
tion with its speci¢c activator protein, TAK1 binding protein
1 (TAB1), triggers TAK1 kinase activity [2]. The TAK1^
TAB1 complex functions in the BMP signaling pathway in
early Xenopus development, in cooperation with the BMP
signaling molecule, Smad1 or Smad5 [3]. In addition, TAK1
is suggested to act as a MAP3K in the c-Jun N-terminal ki-
nase (JNK) and the p38 MAPK cascades, in which TAK1
phosphorylates MAPK kinases MKK4 and MKK3/6, respec-
tively [4,5]. In fact, hematopoietic progenitor kinase 1 (HPK1)
[6] and ceramide [5] have been shown to induce the activation
of the JNK pathway mediated through TAK1.
We originally reported that TAK1^TAB1 was involved in
the NF-UB activation pathway [7], in which TAK1 activated
two IUB kinases, IKKK and IKKL [8]. Ninomiya-Tsuji et al.
demonstrated that TAK1 associated with tumor necrosis fac-
tor (TNF)-K receptor-associated factor 6 (TRAF6) and acti-
vated NF-UB-inducing kinase (NIK), the upstream kinase of
IKKs, in the interleukin-1 (IL-1) signaling pathway [9]. TAK1
is also activated by TNF-K [4,8]. However, TAK1 does not
associate with TRAF2, which is an adapter protein in the
TNF-K receptor complex [9]. These observations suggest
that the intracellular signals bifurcate into the MAPK and
NF-UB signaling pathways at the TAK1^TAB1 complex.
It has been shown that TAB1 associates with the catalytic
domain of TAK1 and induces its kinase activity [2]. However,
little is known about the TAK1 activation mechanism by
TAB1. In this study, we characterized the molecular mecha-
nism of TAB1-mediated TAK1 activation in transient trans-
fection experiments. The association with TAB1 induced
TAK1 autophosphorylation at two threonine residues in the
activation loop. The TAK1 activation domain of TAB1 was
present within its C-terminal 68 amino acids, which consisted
of two functional subdomains for association with TAK1 and
activation of TAK1.
2. Materials and methods
2.1. Mammalian expression vectors
The expression vector for Flag-tagged TAK1 was previously de-
scribed [8]. Point mutations were made by using a QuickChange
site-directed mutagenesis kit (Stratagene) and all of the mutations
were veri¢ed by DNA sequencing analysis. The expression vectors
for HA-tagged and EGFP-fused TAB1 were generated by insertion
of TAB1 cDNA encoding full length, N-terminal (amino acids 1^436),
C-terminal (437^504), C1 (437^460), C2 (459^482) and C3 (480^504)
into pcDNA3.1 (Invitrogen) and pEGFP-C1 (Clontech), respectively.
2.2. Cell cultures and transfection
HeLa cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(high glucose) supplemented with 10% fetal calf serum, 100 units/ml
penicillin, and 100 Wg/ml streptomycin at 37‡C in 5% CO2. Cells were
transfected with expression vectors using Lipofectamine reagents (Life
Technologies).
2.3. Generation of recombinant TAK1 and TAB1
Full length TAK1 cDNA was inserted into pAcHLT baculovirus
expression vector (Pharmingen). Sf21 insect cells were infected with
recombinant virus, and TAK1 was expressed as a 6UHis-tagged pro-
tein. Protein expression was determined by Western blotting with an
anti-TAK1 antibody (Santa Cruz, M-579). cDNAs encoding full
length, N-terminal and C-terminal TAB1 were inserted into a
pGEX-2T bacterial expression vector (Amersham Pharmacia Bio-
tech). GST-fused TAB1 proteins were expressed in Escherichia coli
and puri¢ed with glutathione-Sepharose (Amersham Pharmacia Bio-
tech). The puri¢ed proteins were separated on SDS^PAGE and
stained with CBB. Recombinant TAK1 was incubated with GST-
TAB1 in a kinase bu¡er and then determined kinase activity as de-
scribed previously [10].
2.4. In vitro immunocomplex kinase assay
Flag-TAK1 was immunoprecipitated from whole cell lysates with
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an M5 anti-Flag antibody (Sigma). The immunoprecipitates were an-
alyzed for TAK1 kinase activity with substrate protein (6UHis-
MKK6) as described previously [8].
2.5. Coimmunoprecipitation assay
Association between TAK1 and TAB1 was analyzed by Western
blotting with anti-HA (Santa Cruz, Y-11) or anti-GFP antibodies
(Clontech) of anti-Flag immunoprecipitates. Western blotting was
performed as described previously [7].
2.6. IKK and JNK activation assay
The endogenous IKK and JNK were immunoprecipitated with anti-
IKKK (Santa Cruz, H-744) and anti-JNK1 antibodies (Santa Cruz,
FL). The immunoprecipitates were examined for the IKK and JNK
kinase reactions as described previously [8].
3. Results and discussion
3.1. Activation of TAK1 mutants by TAB1
We investigated the molecular mechanism of TAB1-induced
TAK1 activation in HeLa cells. Flag-tagged wild-type TAK1
was activated by HA-tagged full length TAB1, where TAK1
associated with TAB1 (Fig. 1). A kinase negative mutant
(TAK1-K63W) also associated with TAB1, but no kinase ac-
tivity was detected (Fig. 1). When expressed alone, TAB1 was
detected as doublet bands in Western blotting (Fig. 1). TAB1
further migrated slowly when coexpressed with wild-type
TAK1, but not with TAK1-K63W. TAK1, but not TAK1-
K63W, also migrated slowly when coexpressed with TAB1
(Fig. 1). We previously reported that the band shift was due
to phosphorylations of these proteins [8]. In addition, endog-
enous TAK1 and TAB1 were phosphorylated upon IL-1 stim-
ulation in human embryonal kidney 293 cells [9,11]. The phos-
phorylation was required for TAK1 activation as described
below. Furthermore, the phosphorylation resulted in the sta-
ble expression of these proteins (Fig. 1). The stabilization was
dependent on the TAK1 kinase activity, since this was not
detected when TAK1-K63W was expressed with TAB1.
A TAK1 mutant that lacks the N-terminal 22 amino acids
(TAK1-vN) acts as a TAB1-independent constitutively active
kinase in the TGF-L signaling in MV1Lu and MC3T3-E1 cells
[1,2]. In contrast to the previous reports, the kinase activity of
TAK1-vN was completely TAB1-dependent in HeLa cells
(Fig. 1). The nuclear translocation of NF-UB by TAK1-vN,
a downstream signaling pathway of TAK1, was also TAB1-
dependent (data not shown). In addition, the phosphorylation
of TAK1-vN was similar in extent to that of wild-type TAK1
(Fig. 1). Therefore, the serine cluster in the N-terminal 22
amino acids is not the site of the TAB1-induced TAK1 phos-
phorylation. These results demonstrate that TAK1-vN activa-
tion is completely dependent on TAB1 in HeLa cells. These
distinct results might be derived from the cell-type speci¢city
to the TGF-L responsibility of TAK1 activation. In fact,
TAK1 is activated by TGF-L in MV1Lu and MC3T3-E1 cells
[1,2], but not in HeLa cells [8]. Therefore, it should be noted
that the cell-type speci¢city of the physiological TAK1 func-
tions in the TGF-L/BMP and IL-1/TNF-K signaling path-
ways.
It has been shown that the serine or threonine residues in
the activation loop of protein kinases are important for en-
zyme activation, and their substitution with acidic amino
acids (glutamic or aspartic acid) produces constitutively active
mutants [12]. We generated a TAK1 mutant (TAK1-TT/EE),
in which two threonine residues (Thr-184 and Thr-187) were
substituted with glutamic acids. The association of TAK1-TT/
EE with TAB1 was comparable to that of the wild-type
TAK1, but the kinase activity was severely reduced. The re-
duced activity resulted in impaired phosphorylation of both
TAK1 and TAB1, strongly suggesting that the phosphoryla-
tions were mediated by the TAK1 kinase activity. This result
indicates that the autophosphorylation of Thr residues is nec-
essary for maximal TAK1 activation. However, the migration
of TAK1-TT/EE on SDS^PAGE remained to be reduced
slightly. Kishimoto et al. reported that Ser-192 in the activa-
tion loop was autophosphorylated upon IL-1 stimulation [11].
Interestingly, the autophosphorylation of Ser-192 could not
be mimicked by replacement with negatively charged amino
acid (aspartic acid) [11]. These observations indicate that
TAK1 activation requires multiple phosphorylations in the
activation loop of TAK1, which can not be mimicked by
replacement with negatively charged residues.
3.2. TAK1 activation by TAB1 in a cell free system
To characterize the TAK1 activation domain of TAB1, we
generated recombinant TAK1 in the baculovirus system as a
6UHis-tagged protein (Fig. 2A) and TAB1 in bacteria as a
GST-fusion protein (Fig. 2B). Incubation of TAK1 and full
length TAB1 in a cell free system containing ATP induced the
TAK1 kinase activity (Fig. 2C). In contrast, TAK1 and TAB1
alone did not induce the phosphorylation activity. Shibuya et
al. previously reported that the C-terminal TAB1 was su⁄-
cient for association with and activation of TAK1 in the
TGF-L signaling [2]. We investigated the ability of N-terminal
Fig. 1. Activation of TAK1 mutants by TAB1. HeLa cells (1U106
cells/60 mm dish) were transfected with expression vectors for wild-
type and mutant Flag-TAK1 (1 Wg each) and HA-TAB1 (1 Wg).
The total amount of DNA was adjusted with an empty vector at
2 Wg. The TAK1 kinase activity was determined by an anti-Flag im-
munocomplex kinase assay using 6UHis-MKK6 as a substrate
(upper panel). Associations between Flag-TAK1 and H-TAB1 were
determined by a coimmunoprecipitation assay using anti-Flag and
anti-HA antibodies (middle panel). Protein expression levels were
determined by Western blotting of the immunoprecipitates (TAK1)
or whole cell lysates (TAB1).
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(amino acids 1^436) and C-terminal (437^504) TAB1 in the
cell free system. GST-TAB1-C, but not GST-TAB1-N, acti-
vated TAK1 to a similar extent to GST-TAB1-FL (Fig. 2C).
These results indicate that the C-terminal 68 amino acids of
TAB1 are su⁄cient for triggering the TAK1 activation mech-
anism.
3.3. TAK1 activation by the C-terminal domain of TAB1 in
vivo
To con¢rm the activity of the C-terminal domain of TAB1
in vivo, full length, N-terminal and C-terminal TAB1 were
expressed as fusion proteins with EGFP in HeLa cells. An
anti-Flag immunocomplex kinase assay showed that EGFP-
TAB1-C, but not EGFP-TAB1-N, induced the TAK1 kinase
activity (Fig. 3). A coimmunoprecipitation assay showed that
EGFP-TAB1-C associated with TAK1 (Fig. 3). In addition,
EGFP-TAB1-C was phosphorylated at many sites, and was
detected as quadruplet on SDS^PAGE (Fig. 3). These results
indicate that the C-terminal 68 amino acids of TAB1 are
su⁄cient for association with and activation of TAK1 in
vivo. The N-terminal TAB1 may play a role in regulating
TAK1, including regulation of the intracellular distribution
of TAB1^TAK1. In fact, XIAP was isolated in the yeast
two-hybrid system by using the N-terminal TAB1 as bait
[13]. XIAP is a member of the cellular inhibitor of apoptosis
protein (IAP) family that links the TAB1^TAK1 and BMP
type I receptor [13]. However, it has not yet been demon-
strated whether XIAP plays a role in the IL-1/TNF-K signal-
ing pathways.
3.4. Characterization of the C-terminal TAK1 activation
domain of TAB1
We further characterized the TAK1 activation domain in
the C-terminal TAB1. The 68 amino acids were divided into
three fragments (C1, amino acids 437^460; C2, 459^482; C3,
480^504) and expressed as fusion proteins with EGFP. An
immunocomplex kinase assay showed that only the C3 frag-
ment activated TAK1 (Fig. 4). The kinase activity of C3-acti-
vated TAK1 was decreased severely compared with that of
TAB1-C-activated TAK1, whereas the autophosphorylation
of TAK1 was detected normally (Fig. 4). In addition, TAK1
associated with the C3 fragment to a similar extent as TAB1-
C (Fig. 4). These results indicate that the C3 fragment was
su⁄cient for the association with TAK1 and the induction of
TAK1 autophosphorylation. However, other mechanisms are
necessary to induce maximal TAK1 activity, in which the C1
and/or C2 fragments may play an important role. Interest-
ingly, the C3 fragment was detected as a single band in West-
ern blotting (Fig. 4), indicating that it was not phosphorylated
in a complex with TAK1. Thus, the phosphorylation sites on
TAB1 are present within the C1 and/or C2 fragments. In fact,
C1 was Ser/Thr rich with eight serine and ¢ve threonine res-
idues. These results raise the possibility that the phosphory-
lation of the C1 fragment of TAB1 was necessary for the full
TAK1 activation.Fig. 2. Activation of TAK1 by TAB1 in a cell free system. A: Ly-sates prepared from Sf21 cells infected with control or recombinant
TAK1 baculoviruses were immunoblotted with an anti-TAK1 anti-
body. B: Full length, N-terminal and C-terminal TAB1 fused with
GST were expressed in E. coli and stained with CBB. C: Control
cell lysates or TAK1-expressing lysates were incubated with GST-
TAB1 at an ATP-containing condition and then TAK1 kinase activ-
ity was determined.
Fig. 3. TAK1 activation by the C-terminal TAB1 in vivo. HeLa
cells were transfected with expression vectors for Flag-TAK1 (1 Wg)
and EGFP-fused TAB1 (1 Wg). The total amount of DNA was ad-
justed with empty vectors at 2 Wg. The TAK1 kinase activity was
determined by an anti-Flag immunocomplex kinase assay (upper
panel). Associations between Flag-TAK1 and H-TAB1 were deter-
mined by a coimmunoprecipitation assay using anti-Flag and anti-
GFP antibodies (third panel). Protein expression levels of TAK1
(second panel) and TAB1 (bottom panel) were determined by West-
ern blotting with anti-TAK1 or anti-GFP antibodies, respectively.
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3.5. IKK and JNK activation by TAK1 and TAB1
It has been reported that TAK1 functions as an upstream
kinase of the IKK-NF-UB and JNK/p38 MAPK signaling
pathways [4^11]. Here, we examined the e¡ects of TAK1
and TAB1 mutants on IKK and JNK activation. First,
wild-type and mutant TAK1 were expressed with full length
HA-TAB1 in HeLa cells. Endogenous IKK complex and
JNKs were immunoprecipitated with anti-IKKK and anti-
JNK antibodies, and the kinase activity was determined by
in vitro kinase assays with GST-IUBK (1^54) and GST-c-Jun
(1^79) as substrates, respectively (Fig. 5A). Wild-type TAK1
and TAK1-vN, but not TAK1-K63W, induced IKK and JNK
activities. Interestingly, TAK1-TT/EE, which showed the
slight kinase activity as shown in Fig. 1, induced only JNK
activation. This result suggests that TAK1-TT/EE could not
recognize the substrate for the IKK pathway, strongly sup-
porting the previous observation that the intracellular signals
from IL-1 receptor bifurcate into the MAPK pathway and the
IKK pathway at the level of TAK1. Indeed, it has been shown
that TAK1 activates MKK4 for JNK activation [5] and NIK
for IKK activation [9].
Next, we examined the e¡ect of TAB1 mutants on the
TAK1-induced IKK and JNK activation (Fig. 5B). In vitro
kinase assays showed that full length and C-terminal TAB1,
but not N-terminal TAB1, induced the activity of IKK and
JNK. This result indicates that the C-terminal TAK1 activa-
tion domain of TAB1 is su⁄cient for the TAK1-induced sig-
nal transduction.
3.6. A model for TAK1 activation by TAB1
The results presented above provide a possible model for
the molecular mechanism of TAK1 activation by TAB1. As-
sociation between the catalytic domain of TAK1 and the C-
terminal TAB1 (C3 fragment) triggers the TAK1 activation
mechanism. The association may cause conformational
change of the catalytic domain, inducing a kinase activity of
TAK1 for autophosphorylation at Thr-184, Thr-187 and Ser-
192 in the activation loop. The autophosphorylated TAK1
further phosphorylates the C-terminal Ser/Thr rich domain
of TAB1. The highly phosphorylated TAB1 still associates
with TAK1, therefore, the conformation of TAK1 may be
further in£uenced by the negative charges of phosphate
groups on TAB1.
Endogenous TAK1 constitutively associates with TAB1 in
unstimulated cells, but no TAK1 kinase activity is detected
[11,14]. Upon IL-1 stimulation, TAK1 and TAB1 are re-
cruited to TRAF6, and may trigger the TAK1 activation
Fig. 4. Characterization of TAK1 activation domain of TAB1. The
68 amino acids of TAB1-C were divided into three fragments (C1,
amino acids 437^460; C2, 459^482; C3, 480^504) and expressed as
fusion proteins with EGFP. TAK1 kinase activity (upper panel), the
association between TAK1 and TAB1 (third panel), and protein ex-
pression levels of TAK1 (second panel) and TAB1 (bottom panel)
were determined as described in Fig. 3. ns means non-speci¢c band.
Fig. 5. IKK and JNK activation by TAK1 and TAB1. E¡ects of
TAK1 mutants (A) and TAB1 mutants (B) on IKK and JNK acti-
vation were examined. HeLa cells were transfected with expression
vectors for TAK1 (1 Wg) and TAB1 (1 Wg). The total amount of
DNA was adjusted with an empty vector at 2 Wg. Endogenous IKK
complex and JNKs were immunoprecipitated with anti-IKKK and
anti-JNK antibodies and examined the kinase activities for GST-
IUBK (1^54) and GST-c-Jun (1^79), respectively. Protein expression
levels of endogenous IKKK and JNK1/2 were determined by West-
ern blotting with the antibodies.
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mechanism [9]. Takaesu et al. recently reported that TAB2,
another TAK1 binding protein, is an adapter protein that
links between TRAF6 and TAK1 [14]. They suggest a possi-
bility that the binding to an as yet unidenti¢ed negative reg-
ulator inactivates endogenous TAK1^TAB1 in the absence of
IL-1. TRAF-interacting proteins that inhibit NF-UB activa-
tion are candidates for this negative regulator. These include
A20 [15,16], TRIP [17] and I-TRAF/TANK [18]. Identi¢ca-
tion of the negative regulator provides the new insights into
the molecular mechanism for triggering the TAB1-mediated
TAK1 activation upon cytokine stimulation.
In summary, we showed a novel phosphorylation-depen-
dent mechanism for the activation of TAK1 by TAB1. Future
investigation of the crystal structure of TAK1 associated with
or without TAB1 will provide more information on the
TAB1-induced TAK1 activation mechanism. Furthermore,
characterization of those residues in the C-terminal TAB1
critical to the TAK1 activation may contribute to drug design
for the generation of a speci¢c inhibitor of TAK1 kinase.
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